Doussot Alexandre, Groot-Koerkamp Bas, Wiggers Jimme K, Chou Joanne, Gonen Mithat, DeMatteo Ronald P, Allen Peter J, Kingham T Peter, D'Angelica Michael I, Jarnagin William R
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
J Am Coll Surg. 2015 Aug;221(2):452-61. doi: 10.1016/j.jamcollsurg.2015.04.009. Epub 2015 Apr 24.
Published prognostic models for overall survival after liver resection for intrahepatic cholangiocarcinoma require external validation before use in clinical practice.
From January 1993 to May 2013, consecutive patients who underwent resection of intrahepatic cholangiocarcinoma were identified from a prospective database. The Wang nomogram was derived in an Asian cohort (n = 367) and included clinicopathologic variables and preoperative CEA and cancer antigen 19-9 levels. The Hyder nomogram was derived in an Eastern and Western multicenter cohort (n = 514) using clinicopathologic variables only. The AJCC Cancer Staging System (7th ed) and the preoperative Fudan risk score were also evaluated. Prognostic performance was assessed in terms of discrimination, calibration, and stratification.
One hundred and eighty-eight patients were included, with a median follow-up of 41 months. Median overall survival was 48.7 months and estimated 3-year and 5-year overall survival rates were 59% and 45%, respectively. Overall survival prediction accuracy, according to concordance-index calculation, was 0.72 with the Wang nomogram, 0.66 with the Hyder nomogram, 0.63 with the AJCC system, and 0.55 using the Fudan score. Both nomograms provided effective patient stratification in distinct survival groups.
Both the Wang and Hyder nomograms provided accurate patient prognosis estimation after liver resection for intrahepatic cholangiocarcinoma and can be useful for decision making about adjuvant therapy. The Wang nomogram appears to be more appropriate in patients undergoing formal portal lymphadenectomy and requires preoperative CEA and cancer antigen 19-9 levels for optimal performance.
已发表的肝内胆管癌肝切除术后总生存预后模型在临床实践中应用前需要进行外部验证。
从1993年1月至2013年5月,从前瞻性数据库中识别出连续接受肝内胆管癌切除术的患者。王式列线图来自一个亚洲队列(n = 367),包括临床病理变量以及术前癌胚抗原(CEA)和癌抗原19-9水平。海德列线图来自一个东西方多中心队列(n = 514),仅使用临床病理变量。还评估了美国癌症联合委员会(AJCC)癌症分期系统(第7版)和术前复旦大学风险评分。从区分度、校准度和分层方面评估预后性能。
纳入188例患者,中位随访时间为41个月。中位总生存时间为48.7个月,估计3年和5年总生存率分别为59%和45%。根据一致性指数计算,王式列线图的总生存预测准确率为0.72,海德列线图为0.66,AJCC系统为0.63,复旦大学评分法为0.55。两种列线图均能在不同生存组中对患者进行有效分层。
王式和海德列线图在肝内胆管癌肝切除术后均能准确估计患者预后,可用于辅助治疗的决策制定。王式列线图似乎更适用于接受正规门静脉淋巴结清扫术的患者,并且需要术前CEA和癌抗原19-9水平以达到最佳性能。